Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow and Director of the CRUK RadNet Centre Glasgow. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute of Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with targeted drug therapies, but his research interests in radiotherapy-drug combinations extend across tumour sites including lung cancer and mesothelioma. He is Chief Investigator for a portfolio of early phase clinical trials evaluating various inhibitors of the DNA damage response in combination with radiotherapy and/or chemotherapy in the treatment of glioblastoma, and also leads the randomised phase II SYSTEMS-2 trial of radiotherapy dose escalation in mesothelioma. Until April 2019 he was Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and currently co-chairs the CRUK RadNet Radiotherapy-Drug Combinations Working Group. He is an Executive Board Member of the European Association for Neuro-Oncology (EANO) and sits on the Radiobiology Committee of the European Society for Therapeutic Radiation Oncology (ESTRO). Within the UK he founded and chairs the Scottish Radiotherapy Research Forum (ScoRRF).